Impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes, a first for a non-drug active substance
The REVERSE-IT study has met its primary endpoint: TOTUM•63 reduced fasting blood glucose at 6 months versus placebo, on both a 3-intake/day and a 2-intake/day regimen, the optimal regimen for marketing and real-life patient compliance (press release, May 22).
Detailed results today demonstrate TOTUM•63’s impressive efficacy on glucose metabolism, including plasma glycated hemoglobin (HbA1c), a biomarker established for microvascular risk, used for monitoring type 2 diabetes, with results comparable to some anti-diabetic drugs in a similar population.